DrugsControl Media Services

News Detail

AstraZeneca India launches Trastuzumab deruxtecan for HER-2 positive metastatic breast cancer (03-01-2024)

Chennai, 3 Jan 2024: AstraZeneca India Pharma Ltd officially launched Trastuzumab deruxtecan, therapy tailored for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer for those who have previously received an anti-HER2 regimen. Developed in......
View Details

Source : ET HealthWorld
AstraZeneca India trastuzumab deruxtecan metastatic HER2 positive breast cancer antibody drug conjugate ADC WHO cytotoxic DESTINY-Breast03 trial

Related News